Harnessing Facebook to Investigate Real-World Mentions of Adverse Events of Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Medications: Observational Study of Facebook Posts From 2022 to 2024
This social media study highlights the adverse event mention patterns for posts referencing GLP-1 RA medications. While further research is needed to rigorously examine and validate these findings, this study demonstrates the importance of monitoring social media discussions to predict novel, underreported, or rare drug adverse events, thereby improving patient care, clinical research, and health policy interventions.
Authors
- Rozalina Grubina McCoy (ORCID: https://orcid.org/0000-0002-2289-3183)
- Thu T. Nguyen (ORCID: https://orcid.org/0000-0003-1185-045X)
- Alexandria Ratzki‐Leewing (ORCID: https://orcid.org/0000-0002-9474-7900)
- Junaid S. Merchant (ORCID: https://orcid.org/0000-0002-4315-6211)
- Heran Mane (ORCID: https://orcid.org/0000-0001-8859-3282)
- Shaniece Criss (ORCID: https://orcid.org/0000-0002-2470-5377)
- Xiaohe Yue (ORCID: https://orcid.org/0000-0001-5922-1949)
- Vidur Jain
- Quynh C. Nguyen (ORCID: https://orcid.org/0009-0006-1184-1560)
- Amrutha S Alibilli (ORCID: https://orcid.org/0009-0006-3932-264X)
Institutions
- University of Maryland, Baltimore (US)
- National Institutes of Health (US)
- Foundation for the National Institutes of Health (US)
- National Institute of Nursing Research (US)
- University of Maryland, College Park (US)
- Furman University (US)
Publication Details
- Journal
- JMIR Infodemiology
- Published
- 2025-07-24
- DOI
- https://doi.org/10.2196/73619
- Citations
- 3
- Primary Topic
- Health Literacy and Information Accessibility
- Type
- article
- Field-Weighted Citation Impact
- 8.45